📢 Latest Update

FDA shifts 60-year default: One pivotal clinical trial is now the default for drug approval – replacing the two-trial requirement

Read the full story →

Contact us
Contact us

News & Updates

Stay informed with the latest developments, announcements, and insights from GNQ, spanning platform advancements, strategic milestones, and scientific progress.

Corporate News

GNQ Insilico Plans to Accelerate Precision Medicine and Clinical AI Adoption Across Drug Development and Patient Care

April 15, 2026

Read More →
Corporate News

GNQ Insilico Inc. to go Public Through Business Combination With IB Acquisition Corp. (NASDAQ: IBAC)

March 16, 2026

Read More →
Corporate News

FDA shifts 60-year default: One pivotal clinical trial is now the default for drug approval – replacing the two-trial requirement

March 2, 2026

Read More →
Corporate News

GNQ Insilico Secures MindLab, an Award Winning Pharma Company, as a Client for its Drug Assessment Platform

October 30, 2025

Read More →
Corporate News

GNQ Insilico Launches Revolutionary AI-Driven Assessment Platform to Transform Precision Medicine and Drug Development

September 10, 2025

Read More →
Corporate News

GNQ Insilico Unveils Multi-Pathway Therapeutic Formulation for ALS Leveraging proprietary Drug Assessment Platform

July 9, 2025

Read More →
Corporate News

GNQ’s Drug Assessment Platform Enhances Non-Small Cell Lung Cancer Treatment by Extending Efficacy Beyond Universal Resistance Barrier

July 7, 2025

Read More →
Corporate News

GNQ presents at Quantum Rising Conference alongside Deloitte & IBM Quantum

December 15, 2024

Read More →
Corporate News

GNQ Insilico’s AI-Driven Digital Twins Platform Shows Promising Results in Simulating Effects of a Drug on Synthesized Digital Twins

June 18, 2024

Read More →

Connect with

GNQ

Explore collaboration opportunities and learn how our platform can support your research and development initiatives.

Contact us
Contact us